{"id":"9201eeef2b26","type":"article","url":"https://hartvaat.nl/2026/02/24/multidisciplinaire-cardiometabole-kliniek-ldl-c-verlaging-in-de-dagelijkse-prakt/","title":"Multidisciplinaire cardiometabole kliniek: LDL-C-verlaging in de dagelijkse praktijk","title_en":"Early outcomes from a new multidisciplinary cardiometabolic clinic: real-world experience in lowering low-density lipoprotein cholesterol.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","huisarts","internist"],"tags":["diabetes-en-hart","diabetes-type-2","dyslipidemie","ezetimibe","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","farmaco-economie","gepersonaliseerde-geneeskunde","hdl-cholesterol","laminopathie","ldl-cholesterol","lipidenverlaging","niet-statine-therapie","obesitas","ouderen","pcsk9-remmers","pcsk9-remmers-nieuwe-generatie","statines","vrouwen"],"journal":"Internal medicine journal","doi":"10.1111/imj.70334","source_url":"https://doi.org/10.1111/imj.70334","authors":["Ying Yi Wendy Yap","Nick S R Lan","Girish Dwivedi","Bu B Yeap","P Gerry Fegan","Krishnamurthy Chikkaveerappa"],"significance":4,"published":"2026-02-24","source_date":"2026-02-24","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/"],"congress":"","summary_en":"Real-world data from the first 200 patients at a new multidisciplinary cardiometabolic clinic demonstrate effective LDL-cholesterol lowering with PCSK9 inhibitors in patients with FH and cardiovascular disease who fail to reach targets on statins alone.","created":"2026-07-03T10:24:56Z","updated":"2026-07-03T13:24:25Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Real-world data van de eerste 200 patiënten van een multidisciplinaire cardiometabole polikliniek toont effectieve LDL-cholesterolverlaging in de praktijk, met inzet van PCSK9-remmers bij patiënten met FH en cardiovasculaire ziekte die ondanks statinetherapie hun streefwaarden niet bereiken.","abstract_original":"This study presents real-world data on low-density lipoprotein cholesterol (LDL-C) management in the first 200 patients seen at a new multidisciplinary cardiometabolic clinic from January 2023, with follow-up until April 2024. The cohort had a mean ± standard deviation age of 52 ± 14 years, 51% were male, 69 (35%) had familial hypercholesterolaemia and 66 (33%) had cardiovascular disease. Lipid-lowering therapies were escalated in 120 (60%) patients. Median low-density lipoprotein cholesterol level decreased with initiation of evolocumab (69%), inclisiran (56%), statin (45%) and ezetimibe (21%). In patients with a history of statin intolerance, 19 (43%) re-initiated or increased statin dose."}